



# ocumetics

Accommodating Intraocular Lens Designed To Replicate Natural Vision



TSXV: OTC.V



FSE: 2QB0



OTCQB: OTCFF



Investor Pitch Deck Q1 2026

# DISCLAIMER

---

Nothing contained in this presentation is or shall be relied upon as a promise, guarantee, representation of or warranty specific or implied as to future performance of Ocumetics Technology Corp. The forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement. Certain statements in this document constitute forward-looking statements. These statements relate to future events or our future technological or financial performance and can be identified by expressions such as “targeted”, “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative of these and other such similar expressions. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements, expressed or implied by these forward-looking statements, to change.

The forward-looking statements made in this presentation are made as of the date hereof and Ocumetics does not undertake any obligation to update such statements to reflect any new information, subsequent results or events or otherwise. This presentation does not, and it is not intended to, provide any financial, legal, accounting, or tax advice, and should not be used or relied upon by you as a substitute for your independent research or consultation with your own financial, legal or tax advisers.

This presentation does not constitute an offering memorandum / term sheet nor an offer to sell or solicit to buy securities of Ocumetics. Any information contained in this presentation may change at any time without notice. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable laws, we do not intend to update any of the forward-looking statements to conform these statements to actual results. This presentation is not, in whole or in part, intended to be an offering to solicit funds. It is intended for information purposes only.

# HERE'S THE OPPORTUNITY



## Breakthrough Innovation

- Successful First-In-Human (FIH) implants - August 2025
- Designed for rapid, dynamic focus
- Multiple global patents & patents pending



## Massive Market Opportunity

- \$4.5B+ global IOL market, growing 3–5% CAGR
- Initial focus: \$1.2B premium cataract segment (65+)
- Expansion pipeline into larger adjacent markets



## Clear Roadmap to Commercialization

- 30-patient First-in-Human study (2025–26)
- CE Mark & early EU commercialization (Commencing 2027)
- FDA multi-phase study (Commencing 2026)



## Strong Leadership

- CEO Dean Burns: ex-Alcon Vision (\$750M BU, 15 FDA approvals, \$6B in product launches)
- Backed by 12 leading ophthalmology advisors



## Industry Validation

- 4 of top 7 global eyecare companies requested FIH results (traction)
- Active M&A interest in next-gen vision correction technologies

# THE PROBLEM

## Sight loss with Age

The eye deteriorates as we age, developing the following conditions:

- Presbyopia (age 45+): Loss of accommodation – inability to focus
- Cataracts (age 65+): Cloudy, inflexible natural – blindness if untreated

Existing solutions:

- Glasses, contacts, fixed-focus implants – don't restore natural vision.

Prevalence of Presbyopia in North America:

- Adults aged 45 and older in the U.S. experience presbyopia at very high rates—about 83%. \*(1)
- Presbyopia is an age-related decline in the eye's ability to focus on near objects. In North America (particularly the U.S.), it's nearly universal by age 45—affecting over four-fifths of adults in that age group. Given the U.S. population aged 45+, that translates to more than 120 million people experiencing difficulty with near vision. \*(2)

\* (1) <https://eyesoneyecare.com> \* (2) <https://www.presbyopiaphysician.com>

About  
**83%**

Adults aged 45 and older in the U.S. experience presbyopia

More than  
**120M**  
people experiencing difficulty with near vision.

# THE SOLUTION

## OCUMETICS LENS



### No Silicone Oil Chamber

- Designed to avoid fragile silicone oil chambers used in competitor implants, preventing leakage, clouding, and long-term instability

### Minimized Post-Surgical Risks

- Designed to eliminate common lens side effects like glare, halos, or secondary procedures, delivering safer recovery and better outcomes

### Biometric Vision Restoration

- Designed to restore biometric vision
- Designed to replicate natural eye biomechanics using shape-changing lens technology, restoring life-like visual adaptability instead of static correction



### High-Quality Optics, Safe & Affordable

- Combines premium optics and strict safety with scalable production, keeping advanced vision correction accessible and affordable



- 18-year journey
- Over 8 design iterations
- 100% tested
- Manufactured in Erlangen Germany

# WHAT IS THE NATURAL LENS BIOKINETICS?



## What is Accommodation?

Accommodation is where the muscles and attachments pull on the lens to thin it out, allowing an individual to see in the distance. When the eye relaxes the lens is no longer pulling and the individual is allowed to see up close. The image on the left is under tension and the one on the right is relaxed.

# Strong Global IP



## UNITED STATES FDA

- The Food and Drug Administration (FDA) Centre for Devices and Radiological Health (CDRH) is responsible for regulatory firms who manufacture, repackage and/or relabel medical devices.
- IOLs are class III medical devices that require premarket approval.
- Manufacturers require premarket approval from the FDA before they can commence marketing activities.
- Considered to have toughest standards in the world.

- ISO certification being pursued: ISO11979 (1-10) and ISO-TR22979-2017.

## REST OF WORLD

- Each country or jurisdiction has a regulatory body similar to the FDA that regulates IOLs.

50  
Global Patents  
3 provisional  
47 utility



CE Mark

**August 18, 2025**

# Ocumetics Achieves Historic First: Accommodating Intraocular Lens Successfully Implanted In Human Patients

How was this successful?

- Achieved biocompatible success (animal safety)
- Successfully manufactured the appropriate diopter lens for the study
- Successfully received ethics committee approval for protocol
- Successfully recruited patients for group 1
- **Completed surgeries for group 1 patients with great results**




# SUCCESSFULLY IMPLANTED – AUGUST 15, 2025

69  
yrs old


79  
yrs old

First Human Patients



## Four Hours Post Surgery

First two patients successfully received the Ocumetics Lens



# SUCCESSFULLY IMPLANTED – AUGUST 15, 2025

ACTUAL VISION CORRECTION DEMONSTRATED IN ONE PATIENT



BEFORE



AFTER

# What do the experts say?

Dr. Ron Krueger

“In my opinion, as a cataract and refractive surgeon with more than 30 years of experience, and as a Professor and Chairman of an academic department of Ophthalmology, the recently reported first-in-world outcomes of the Ocumetics Lens in cataract surgery highlight a landmark accomplishment. The one-month postoperative results show functional distance vision (20/40 or better) without correction, no complications, and signs of promising near vision—all of which underscore the transformative potential of this technology. ***This achievement represents a major step forward for the field and sets a new benchmark for the novel innovation of accommodating intraocular lens technologies.***

Ronald R. Krueger, MD, MSE  
McGaw Professor and Chairman  
Department of Ophthalmology  
Director of the Truhlsen Eye Institute  
University of Nebraska Medical Center Omaha, NE



# ACCOMMODATING INTRAOCULAR LENS (IOL) COMPETITION



## Atia

- Shape-changing, fluid filled based with fixed-power anterior optic for target refraction
- FIH clinical data 2023
- FDA multi-phase study (2026–28)



## Alcon Fluid Vision

- Silicone oil-filled haptics
- Accommodative effort moves fluid from haptics to optic, increasing A-P diameter and power of the lens



## Jellisee

- One-piece, shape-changing IOL
- Silicone oil chamber



## Juvene


- Shape-shifting, fluid-filled optic
- Capsule-filling base



## Lumina

- Modular, two-piece IOL
- Hydrophilic acrylic material
- Sulcus-fixated haptics

## OCUMETICS LENS



- Two-piece, shape-changing IOL
- No Silicone oil chamber
- Mimics the natural Bio-kinetics of the eye
- Designed to accommodate up to 3D
- Designed for rapid dis-accommodation < 1 second

<sup>(1)</sup>Review of Ophthalmology / Article April 4, 2024 / The Journey to True Accommodation

# IOL TECHNOLOGY ANALYSIS

Technology	Distance	Intermediate	Near	Side Effects
Monofocal	✓	✗	✗	No
Extended Depth of Focus	✓	✗	✗	No
Bifocal	✓	✗	✓	Yes*
Trifocal	✓	✓	✓	Yes*
Ocumatic Lens	✓	✓	✓	No

\* Side effects = Halos, ghosting, starbursts and light scatter


# MARKET ANALYSIS

Ocumetics' strategy is to initially enter the \$1.2Bn, 65+ Cataract surgery segment

Total Intraocular Lens Market

Premium IOL (45+Only) Segment

Premium IOL (65+Only) Segment



Ocumetics has a pipeline of lenses designed to address the larger markets

# PROCEDURE ANALYSIS

## US 3.5 – 4.0M Procedures Annually

Most recent ophthalmology and cataract surgery statistics put the U.S. volume at ~3.7–4.1 million cataract surgeries per year. The figure matches industry sources (e.g., American Academy of Ophthalmology, Market Scope).


## Global 27 – 30M Procedures Annually

Global cataract surgery volumes are typically cited in the 27–30 million range annually, with strong growth in Asia-Pacific, India, and China driving totals. This range aligns with current industry research.

## Average IOL Pricing

US ASP Monofocal | USD \$150

Global ASP Premium | USD \$2,000



# ACQUISITIONS BY MAJORS

Of Less Advanced Ocular Technologies


Company	Technology Focus <sup>(2)</sup>	Development Stage at Acquisition	Acquirer	Year	Acquisition Value (USD) <sup>(1)</sup>	Status
PowerVision	Silicone oil-based AIOL	Preclinical	Alcon	2019	\$285M upfront	+ up to \$135M milestones (2) FIH Clinical trials paused
Visiogen	Synchrony dual-optic AIOL	FDA review	Abbott Laboratories	2009	\$400M cash	Synchrony AIOL discontinued post acquisition
Eyeonics	Crystalens AIOL	FDA-approved \$34M revenue '07 Growing 100% YoY	Bausch & Lomb	2008	Undisclosed	In Market, 1 diopter focus

<sup>(1)</sup>Acquisition values are estimates

<sup>(2)</sup>AIOL = Accommodating Intraocular Lens

# CURRENT CLINICAL MILESTONES

First-In-Human up to 30 Patient Study Milestone Estimates



# CORPORATE STRUCTURE

Shares Outstanding		129M
Options	3.2M (\$0.125: April and August 2026) 1.6M (\$0.32: June 2028) 732k (\$1.16: Oct 2030)	5.5M
Restricted Share Units	Subject to Performance Milestones	5M
Warrants	1.8M (\$0.50: July 2027) 2.0M (\$0.75: December 2028) 9.1M (\$0.58: June 2027)	12.9M
Convertible Debentures	\$4M @ 0.32 - 18% (May and June 2026)	12.5M
Fully Diluted		165M

\* As of Feb 27, 2026

# DEAN BURNS

---



## Dean Burns

CEO, President & Director

Former Senior Director at Alcon Vision, managing a \$750M business unit across devices, disposables, intraocular lenses (IOLs), and pharmaceuticals. Successfully led 15 FDA approvals and 15 product launches with a combined \$6B commercial value, while partnering with 12 of the leading global advisors in Ophthalmology.

# MANAGEMENT & DIRECTORS



**Roger Jewett CA, CPA**  
CFO & Director

With over 25 years of experience leading public and private companies, he has guided organizations through financings, M&A, and growth, closing more than \$70 million in financings and completing over 40 acquisitions and divestitures. His track record includes turning around companies such as Enerjet and RCR, scaling startups like Rare Method and Jump On Flyaways, and co-founding Quantum Blockchain Technologies, which later merged with Ocumetics.



**Dr. Garth Webb**  
Founder, CSO & Director

He is the Founder of Ocumetics and sole inventor of the Bionic Lens™ technology platform, bringing over 45 years of experience in clinical eye care, vision science, and refractive technology innovation. A proven entrepreneur, he co-founded one of Canada's largest optometry clinics and launched multiple health science ventures. As a leader in advancing medical optics, his mission is to transform vision and enhance quality of life.



**Raymond Marks**  
Director

Raymond Marks has over 50 years of experience in as an entrepreneur, owner, operator and manager across a variety of industries including the resources and industrial sectors. Throughout his career, Mr. Raymond Marks has worked with many such companies and secured millions in funding for growing companies and their strategic initiatives. Mr. Marks previously co-founded Tudor Gold Corp. (TSXV:TUD) and served as executive Vice President, and a director of the company from February 2016 until October 2018.

# MANAGEMENT & DIRECTORS



**Dr. James B McRoberts, O.D.**

Director

With over 40 years of experience in optometry, including private practice in British Columbia, he has served as Past President of the BC Association of Optometrists and as Registrar of the BC College of Optometrists. His career includes leadership roles across professional boards, regulatory bodies, and laser vision centers, along with contributions as a published author and lecturer on optometry practice and policy.



**Michael Edwards**

Director

He is a Director at Pinnacle Wealth Brokers, one of Canada's largest Exempt Market Dealers, and President of Customized Insurance & Tax Solutions, specializing in insurance and investment products. A Chartered Life Underwriter with extensive expertise in tax, finance, and estate planning, he brings a strong foundation of technical knowledge and practical experience. His board involvement spans private companies, industry associations such as the PCMA, and several major charitable organizations.



**Robert Quinn**

Director

He is an independent businessman with extensive board, management, and legal experience in the international mining industry. Skilled in corporate governance, environmental oversight, M&A, financing, contracts, compliance, and litigation, he has a proven track record supporting companies in mine development and global exploration programs. He holds a Juris Doctor degree from the University of Denver School of Law and a Bachelor's in Business Administration from the University of Denver.

## CONTACT INFORMATION

---

Contact:

Dave Burwell  
Director, Investor Relations  
403-410-7907  
dave.burwell@ocumetics.com

Website:

[ocumetics.com](http://ocumetics.com)

Address:

639 5 Ave SW #1250  
Calgary, AB  
T2P 0M9  
Canada



TSXV: OTC.V



FSE: 2QB0



OTCQB: OTCFF